Loading...

SPRB SPRUCE BIOSCIENCES INC Product Launches 8-K Filing

SPRC

SPRB

SPRUCE BIOSCIENCES INC

(SPRB)

2024 8-K

Summary

Summary

Private Placement News

Financial Results

Reverse Stock Split

Voluntary Delisting

Equity Offerings

Financial Statements

Management Changes

Corporate Update

Management Change

Trial Discontinuation

Q3 Financial Results

Nasdaq Extension

Q2 Financial Results

Asset Purchase Agreement

Phase 2 Clinical Trial Results

Earnings Reports

Delisting Notice

Financial Results Announcement

Financial Update

Financial Results Announcement

Financial Results and Clini...

Annual Meeting Results

Resignation and Appointments

Earnings Report

Earnings Report

Private Placement of Common...

Collaboration and License A...

External Links:

Spruce Biosciences announced that its clinical trials for tildacerfont in treating Congenital Adrenal Hyperplasia did not meet their primary goals, leading to the discontinuation of these studies and a wind-down of investment in this treatment.

AI Assistant

SPRUCE BIOSCIENCES INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.